Biotech bigs float R&D venture | Chemical & Engineering News
Volume 95 Issue 3 | p. 11 | Concentrates
Issue Date: January 16, 2017

Biotech bigs float R&D venture

Department: Business
Keywords: infectious disease, pharmaceuticals, Biogen

Former Biogen CEO George Scangos is heading a team of drug industry veterans behind Vir Biotechnology, a new company that seeks treatments for infectious disease. The group hopes to employ immune programming to manipulate pathogen-host interactions. Lead investors include Arch Venture Partners and the Bill & Melinda Gates Foundation. Arch, whose co-founder Robert Nelsen conceived of Vir, has committed to invest $150 million. Nelsen says he expects Vir to fund academic research, conduct its own R&D, and spend up to $100 million on individual in-licensing deals.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment